Discreet packaging
Plain outer packaging on every order.
Research use onlyHormone research
Tesamorelin Australia: 10mg Research Peptide
Tesamorelin Australia supply from Glow Labs is a 10mg freeze-dried research vial. It is a lab-made analogue of growth hormone releasing hormone, or GHRH, the brain signal that prompts growth hormone release. Tracked parcels leave Gippsland, Victoria, and arrive in 2-3 days.
Size
$110 AUD per vial, plus $10 tracked shipping per order
Order on WhatsApp
Research use only. Not for human consumption.
- No account needed
- Tracked, 2-3 days
- COA on request
Fast delivery, 2-3 days
Orders leave Traralgon in the afternoon during business hours, then travel tracked to your door.
Certificates on request
Certificates of analysis available on request.
Quality guarantee
If a vial arrives damaged, broken or not what you ordered, message us within 7 days with a photo and we'll replace it free.
What it is
Research overview
What tesamorelin is
Tesamorelin is an analogue of growth hormone releasing factor, the brain hormone that prompts the pituitary to release growth hormone. PubChem lists its earlier code, TH9507, and a mass of about 5136 g/mol.
It is one of the largest peptides in our range, close in size to tirzepatide.
Sources: PubChem compound record: Tesamorelin (CID 16137828), US National Library of Medicine. Falutz J et al, Metabolic effects of a growth hormone-releasing factor in patients with HIV, N Engl J Med, 2007.
Questions about Tesamorelin?
Ask on WhatsAppWhat the trials examined
A 2007 phase 3 trial in the New England Journal of Medicine enrolled 412 people with HIV. They had gained belly fat during HIV treatment. It measured visceral fat by CT scan, along with blood fats and IGF-1.
That work led to US approval of the finished medicine, sold as Egrifta. It is approved to reduce excess belly fat in adults with HIV-related lipodystrophy. The label notes it is not for general weight management.
Sources: Falutz J et al, Metabolic effects of a growth hormone-releasing factor in patients with HIV, N Engl J Med, 2007. Theratechnologies, EGRIFTA WR (tesamorelin) US prescribing information, DailyMed, US National Library of Medicine.
Tesamorelin versus other growth hormone peptides
Growth hormone research peptides fall into two broad groups. GHRH analogues, such as tesamorelin and CJC-1295, act on the GHRH receptor in the pituitary.
Secretagogues such as ipamorelin act on a different receptor, the one used by GHRP-6. The 1998 ipamorelin paper used GHRH and GHRP blockers to show that split.
Sources: Falutz J et al, Metabolic effects of a growth hormone-releasing factor in patients with HIV, N Engl J Med, 2007. Teichman SL et al, J Clin Endocrinol Metab, 2006. Raun K et al, Ipamorelin, the first selective growth hormone secretagogue, Eur J Endocrinol, 1998.
Handling freeze-dried tesamorelin
The US label stores its finished vial in the original box to protect it from light. For research powder, suppliers advise dark storage at -20 °C or colder with desiccant.
Peptide labs also warn against long storage of any dissolved peptide.
Sources: Theratechnologies, EGRIFTA WR (tesamorelin) US prescribing information, DailyMed, US National Library of Medicine. JPT Peptide Technologies, How to store peptides: best practices for researchers. Bachem, Handling and storage guidelines for peptides, Knowledge Center.
Specification
Product specs
| Name | Tesamorelin |
|---|---|
| Sizes | 10mg |
| Form | Lyophilised powder |
| Vial | 3 ml glass vial |
| Cap | Brushed silver-grey |
| CAS number | 218949-48-5 |
| Formula | C221H366N72O67S |
| Molar mass | 5136 g/mol |
| Structure | A synthetic analogue of growth hormone releasing factor. Formula and mass as listed by PubChem. |
| Storage | Store the sealed powder cold and dry, protected from light. |
| Certificate | On request, how to ask |
| Status | In stock |
| Use | Laboratory research only |
Sources: PubChem compound record: Tesamorelin (CID 16137828), US National Library of Medicine. Bachem, Handling and storage guidelines for peptides, Knowledge Center. JPT Peptide Technologies, How to store peptides: best practices for researchers.
Regulatory status
In Australia
The approval above was given in the US, for the finished medicine Egrifta. Our tesamorelin is a raw research peptide for bench use only.
Tesamorelin itself does not appear by name in Australia's Poisons Standard. The standard does carry a group entry for growth hormone releasing hormones, or GHRHs, placed in Schedule 4 as prescription only medicines. Appendix D, clause 5 also lists GHRHs among poisons that must not be possessed without authority, such as a prescription. Tesamorelin is one of the GHRH analogues covered above.
Sources: Theratechnologies, EGRIFTA WR (tesamorelin) US prescribing information, DailyMed, US National Library of Medicine. Therapeutic Goods (Poisons Standard, October 2026) Instrument 2026 (F2026L01327): Schedule 4 group entry for growth hormone releasing hormones (GHRHs) and Appendix D, clause 5, Federal Register of Legislation, Australian Government. Falutz J et al, Metabolic effects of a growth hormone-releasing factor in patients with HIV, N Engl J Med, 2007.
Testing
COA on request
Certificates of analysis are available on request. Ask us on WhatsApp before or after you order.
How ordering works
How to order
- 1
Fill your bag
Add compounds and quantities. No account needed.
- 2
Send on WhatsApp
One tap writes your whole order into a WhatsApp message.
- 3
Confirm and ship
We confirm stock and your total, share payment details, then ship tracked.
FAQ
Your questions
What is tesamorelin?
A synthetic analogue of growth hormone releasing hormone, first coded TH9507.
Is tesamorelin a steroid?
No. It is a peptide, a chain of amino acids. Steroids are a different kind of molecule.
What is the difference between tesamorelin and ipamorelin?
Tesamorelin acts like GHRH. Ipamorelin is a small five residue peptide that works through a GHRP-like receptor instead.
Is tesamorelin approved in Australia?
The approval on record is a US one, for the finished medicine Egrifta. Australia's Poisons Standard does not name tesamorelin, but its GHRH family is in Schedule 4 as prescription only.
How should tesamorelin be stored?
Keep the sealed research vial cold, dry and dark. The US label for the finished medicine stresses protection from light. Peptide makers say to let a cold vial warm up before opening it, and not to keep it long once dissolved.
Sources: PubChem compound record: Tesamorelin (CID 16137828), US National Library of Medicine. Falutz J et al, Metabolic effects of a growth hormone-releasing factor in patients with HIV, N Engl J Med, 2007. Raun K et al, Ipamorelin, the first selective growth hormone secretagogue, Eur J Endocrinol, 1998. Theratechnologies, EGRIFTA WR (tesamorelin) US prescribing information, DailyMed, US National Library of Medicine. JPT Peptide Technologies, How to store peptides: best practices for researchers. Therapeutic Goods (Poisons Standard, October 2026) Instrument 2026 (F2026L01327): Schedule 4 group entry for growth hormone releasing hormones (GHRHs) and Appendix D, clause 5, Federal Register of Legislation, Australian Government.
In the catalogue
Related compounds
Hormone research
Sold out, stocking soon. Message us to pre-order.
Questions before you order?
Ask on WhatsApp